Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Marksans Pharma Limited

NSE: MARKSANSPharmaceuticals

Share price

₹307.80

-5.42% close of 8 Oct 2026

Market cap ₹13,851 CrP/E 26.8

Business score

How strong the business is, in one number. The parts behind it are in Pro.

72

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹13,851 Cr

P/E ratio

26.8

P/B ratio

4.6

ROCE

18.8%

ROE

15.2%

Dividend yield

0.3%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹347.6052-week low ₹156.89

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 19.6% over the past year, and 13.4% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 16.2% to 22.4% over the last four years.

Whether it grew faster than its sector

It grew 13.4% a year against a sector median of 13.1% — 0.3 percentage points faster.

Room to re-rate, or risk of de-rating

At 26.8× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 22.0×, the 75th percentile of its own range.

Whether growth justifies the valuation

Priced at 1.7 times its growth rate, on earnings growth of 16%.

Profit growthPrice per ₹1 profitPer 1% growth
Marksans Pharma Limited — this one16%/yr26.8×₹1.7
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 43 of 130 on returns, 51 of 127 on growth, 56 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A narrow advantage: it earns 18.8% on capital, ahead of 67% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹1231 crore of cash from the business and spent ₹609 crore on plant and equipment, with ₹622 crore to spare; it still raised ₹73 crore mostly borrowed — borrowings rose from ₹111 crore to ₹343 crore. And the profit is real: of every 100 rupees it reported over 12 years, about 85 arrived as cash. Its cash comes back more slowly than it used to: it went from being waiting 121 days for its cash to waiting 149 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 9 checks clear · 89%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue rose 35.6% year on year and profit margin reached 19.0%.

Announced 12 Aug 2026 · Consolidated · Unaudited

Revenue

₹841 Cr

Revenue vs last year

+35.6%

Revenue vs last quarter

-1.8%

Net profit

₹159 Cr

Profit vs last year

+174.8%

Profit vs last quarter

+7.0%

Net margin

19.0%

EPS

₹3.47

Earnings call transcript · 13 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹13,851 Cr
Prev close
₹307.80
52w High
₹351
52w Low
₹155
Enterprise value
₹13,204 Cr
Beta
1.2
Price CAGR 1y
98.0%
Price CAGR 3y
45.0%
Price CAGR 5y
36.0%
Price CAGR 10y
20.0%

Ratios

Return on assets
10.9%
PEG ratio
1.7
P/E ratio
26.8
P/B ratio
4.6
EV / EBITDA
18.5
Industry P/E
38.0
ROCE
18.8%
ROCE 5y average
21.0%
ROE
15.2%
Debt / Equity
0.1
Interest coverage
24.4
Dividend yield
0.3%
ROE 3y average
16.0%
ROE last year
15.0%

Annual P&L

Annual revenue
₹2,951 Cr
Annual profit
₹420 Cr
Operating margin
20.0%
Net profit margin
14.2%
EBITDA margin
20.4%
Sales growth 3y
16.8%
Sales growth 5y
16.5%
Profit growth 3y
16.0%
Profit growth 5y
12.0%
EPS
₹9.2
Sales growth TTM
20.0%
Profit growth TTM
48.0%
Dividend payout
10.0%

Quarter P&L

Sales latest quarter
₹841 Cr
Profit latest quarter
₹159 Cr
YoY quarterly sales growth
35.6%
YoY quarterly profit growth
174.1%
OPM latest quarter
25.3%

Balance Sheet

Book Value
₹67.2
Face Value
₹1.0
Total debt
₹343 Cr
Total cash
₹990 Cr
Borrowings
₹343 Cr
Reserves / Equity
66.2

Cash Flow

Operating cash flow
₹458 Cr
Free cash flow
₹329 Cr
FCF yield
2.2%
Net cash flow
₹138 Cr

Shareholding

Promoter holding
43.9%
FII holding
17.5%
DII holding
6.2%
Public holding
32.5%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,780.0033.84,27,0820.902,901.26.015,299.910.520.5
Divi's Lab.9,515.0084.82,52,5930.31902.065.53,080.027.822.0
Torrent Pharma.4,692.0080.01,78,4690.81566.05.84,921.054.915.2
Zydus Lifesci.1,137.6523.31,13,4810.09990.2-35.18,017.022.021.1
Laurus Labs2,033.75100.51,09,8860.10362.1125.52,026.329.117.8
Cipla1,321.0029.81,06,7200.98785.6-39.27,119.32.315.5
Mankind Pharma2,460.0047.61,01,6090.04574.129.64,030.612.913.5
Marksans Pharma317.5027.814,3880.28159.4169.5840.835.618.8
Median413.3834.42,1400.0713.229.6162.418.615.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales500531586560591642682708620720754856841
Expenses398417453450462495543582520576594661628
Material Cost19193228274265221
Change in Inventories-2.38-102-2515-24-16
Purchases of Stock-in-Trade1617210627150138
Employee Cost9.7298104112107114
Other Expenses16160164165163170
Operating Profit102114133110128147139127100144161195213
OPM %20212320222320181620212325
Other Income101951715-02815622203525
Exceptional items (within Other Income)000000
Interest2235333366667
Depreciation14182221202021232327242425
Profit before tax9711411310012012514311677133151200207
Tax %27262623262227222426252523
Net Profit708483788998105915899114149159
EPS in Rs1.521.841.841.731.962.132.3121.292.172.503.273.47
Diluted EPS in Rs21.292.172.503.273.47

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales7978937679131,0001,1341,3761,4911,8522,1772,6232,9513,172
Expenses6127577228348689421,0371,2321,5131,7192,0902,3502,458
Material Cost75959
Change in Inventories-18-136
Purchases of Stock-in-Trade57454
Employee Cost35421
Other Expenses60652
Operating Profit1851364578132192340259340459533601714
OPM %231569131725171821202022
Other Income39785074259506682102
Exceptional items (within Other Income)00
Interest161071010988911122425
Depreciation162830272327364552748399100
Profit before tax1561071550104157302248338424504561691
Tax %282324282323212521262425
Net Profit11283113680121239187265315383420521
EPS in Rs2.671.920.220.801.872.955.764.515.886.928.409.2211
Diluted EPS in Rs8.409.22
Dividend Payout %4212363346991010

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
13%
5 years
16%
3 years
17%
TTM
20%

Compounded profit growth

10 years
18%
5 years
12%
3 years
16%
TTM
48%

Stock price CAGR

10 years
20%
5 years
36%
3 years
45%
1 year
98%

Return on equity

10 years
17%
5 years
17%
3 years
16%
Last year
15%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital414141414141414145454545
Reserves3264013924305025958461,1611,7002,0202,4222,978
Borrowings1011001101181003034111123244322343
Other Liabilities207180209142160236307323322372451489
Minority Interest30
Total Liabilities6767227527318029021,2281,6362,1902,6813,2403,856
Fixed Assets1662702672792703033094284867769821,044
CWIP0000001231092759
Investments0000000012710
Other Assets5104524844515335999071,2051,6941,8692,2302,753
Total Assets6767227527318029021,2281,6362,1902,6813,2403,861

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity1553114502723317999237230207458
Cash from Investing Activity-33-123-21-39-13-60-45-84-259-141-49-249
Cash from Financing Activity17-58-33-21-114-1580198-69-65-71
Net Cash Flow138-150-1015-760118941762193138
Free Cash Flow118-101-141114174133531842235328

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days8489118716478729782767580
Inventory Days107120151152215155248216192217270278
Days Payable888512954787110310291949896
Cash Conversion Cycle103124140169202163217211183199247261
Working Capital Days175977709787104121122129142149
ROCE %44234101825382322212019

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters444444444444444444444444
FIIs1516161921222220178.131717
DIIs4.024.765.173.754.104.304.555.505.285.916.576.19
Public373635343130293134423332
No. of Shareholders2,07,9372,37,3772,54,6992,35,5002,48,8452,59,8132,57,2732,56,2212,65,7882,55,1532,46,2792,46,635

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +81.6% (₹169.46 → ₹307.80)Brick size ₹14.82 (fixed)Bricks 15
₹200₹250₹350₹308May '26Aug '26
Price moved up one brickPrice moved down one brickLast close ₹307.80 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-647inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

79,61,282inr

2026-03-31

News

News and filings about Marksans Pharma Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • active pharmaceutical ingredients (ibuprofen, metformin HCl, naproxen, gabapentin, loratadine, loperamide, cetirizine, omeprazole, famotidine, acetaminophen)
  • excipients and formulation inputs (softgel/hard capsules, tablets, liquids, ointments, creams)
  • packing materials (tubes, bottles, sachets, blisters)

Sells to

  • Access Healthcare for Medical Products LLC · finished dosage formulations

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE750C01026

Plants

  • Bell, Sons & Co. (Druggists) facility
  • Marksans Goa facility (ex-Teva/Tevapharm India)
  • Marksans Goa manufacturing facility
  • Time-Cap Laboratories Inc. facility · Farmingdale, New York, USA

News impact

Big market events that reach Marksans Pharma Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

20 Aug 2026unspecified₹0.9
1 Aug 2025unspecified₹0.8
17 Sep 2024unspecified₹0.6
7 Jun 2023unspecified₹0.5
19 Aug 2022unspecified₹0.25
15 Sep 2021unspecified₹0.25
22 Sep 2020unspecified₹0.1
19 Sep 2019unspecified₹0.05

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
12 Aug 2026MICROCURVES TRADING PRIVATE LIMITEDBUY43,49,697₹313.24
12 Aug 2026MICROCURVES TRADING PRIVATE LIMITEDSELL43,49,697₹313.40

Insider trades

DisclosedWhoTypeSharesValue ₹ Cr
17 Sep 2026Schenelle Megan Saldanha · Directors Immediate RelativeBUY1,45,000—
17 Sep 2026Sandra Saldanha · DirectorSELL2,28,273—
17 Sep 2026Marise Ann Saldanha · Directors Immediate RelativeBUY20,000—
17 Sep 2026Merrill Jean Saldanha · Directors Immediate RelativeBUY63,273—

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.